SJ-733

SJ-733 is an investigational small molecule antimalarial drug that acts as a selective inhibitor of the *Plasmodium falciparum* ATP4 (PfATP4) protein, a cation-transporter ATPase essential for parasite sodium homeostasis. By inhibiting PfATP4, SJ-733 disrupts sodium regulation in the malaria parasite, leading to rapid parasite death and clearance from infected erythrocytes. The drug induces eryptosis (suicidal erythrocyte death) or senescence in infected red blood cells, facilitating their removal from circulation. Preclinical and clinical studies have shown that SJ-733 is highly potent against both asexual and sexual blood stages of *Plasmodium* species, has high oral bioavailability, and demonstrates a favorable safety profile with low potential for resistance development due to the high fitness cost associated with resistance mutations. Developed by St. Jude Children's Research Hospital in collaboration with Eisai, Medicines for Malaria Venture, QIMR Berghofer Medical Research Institute, and University of Kentucky, it is currently being evaluated in Phase II/III trials for uncomplicated falciparum and vivax malaria[1][3][4][6][7].

Other names

(+)-SJ733SJ-733SJ733SJ 733